Aspirin for all over 50 revisited

Elwood, Peter; Morgan, Gareth
November 2008
Heart;Nov2008, Vol. 94 Issue 11, p1364
Academic Journal
The article reports on a study of the risks of aspirin prophylaxis among diabetic patients with ages ranging between 30 to 74 years. It states that vascular risk of aspirin prophylaxis is estimated to people whose age is 48 years old for men and 57 years old for women. It also mentions that other risks of aspirin prophylaxis are gastric bleeding, haemorrhagic stroke, and heart attack or stroke.


Related Articles

  • ASPIRIN ANOMALY. Gorman, Christine // Time International (South Pacific Edition);3/21/2005, Issue 11, p67 

    The article presents information on the use of aspirin in treating various diseases. A regular low dose of aspirin helps middle-aged men avoid heart attacks and lessens the risk of stroke in middle-aged women. Chewing a 325-mg aspirin tablet in the midst of a heart attack may save life, for both...

  • Picotamide reduced all-cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease.  // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p61 

    This article cites a medical study which reports that picotamide reduced all-cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease. The study found that secondary outcomes were the composite endpoint of death and nonfatal cardiovascular events (myocardial...

  • Coumadin alone or aspirin plus coumadin reduced coronary events and death after acute myocardial infarction or unstable angina. Hudson, Michael P. // ACP Journal Club;Jan/Feb2003, Vol. 138 Issue 1, p9 

    Focuses on a study which investigated the role of coumadin or aspirin plus coumadin in reducing coronary events and death after acute myocardial infarction or unstable angina. Assessment of the clinical characteristics of patients; Patient intervention; Outcome measures.

  • Commonly Asked Questions About Heart Health and Treating Heart Disease. Middlebrooks, Jayne; Grines, Cindy L. // National Women's Health Report;Feb2005, Vol. 27 Issue 1, p7 

    Presents questions and answers related to the treatment of heart disease. Concept of the low-dose aspirin therapy; Assessment of the risk of a heart attack or heart disease; Benefits of bypass surgery for people with diabetes and coronary disease.

  • Warfarin, Aspirin, or Both after Myocardial Infarction. Hurlen, Mette; Abdelnoor, Michael; Smith, Pål; Erikssen, Jan; Arnesen, Harald // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p969 

    Background: The role of antithrombotic therapy in secondary prevention after myocardial infarction is well established. Although the available literature suggests that warfarin is superior to aspirin, aspirin is currently the more widely used drug. We studied the efficacy and safety of warfarin,...

  • No benefit to adding warfarin to aspirin after heart attack. Blakely, Pamela F.; King, Valerie J. // Journal of Family Practice;Jun2002, Vol. 51 Issue 6, p518 

    The article deals with a study which examines whether adding warfarin to aspirin is more effective in preventing subsequent cardiovascular events. It provides details of the population studied and the study design and validity. All-cause mortality was the primary outcome measured while...

  • Warfarin combined with low-dose aspirin in MI did not provide clinical benefit beyond that of aspirin alone. Oh, Vernon M. // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p47 

    Compares the effect of warfarin combined with aspirin and aspirin alone on patients who have survived an acute myocardial infarction. Study design and main outcome measures; Intracranial hemorrhage rates; Information on bleeding occurrences in combination therapy.

  • Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. Seung-Jung Park; Park, Duk-Woo; Young-Hak Kim; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Ki-Hoon Han; Seong-Wook Park; Sung-Cheol Yun; Sang-Gon Lee; Seung-Woon Rha; In-Whan Seong; Myung-Ho Jeong; Seung-Ho Hur; Nae-Hee Lee; Junghan Yoon; Joo-Young Yang; Bong-Ki Lee; Young-Jin Choi; Wook-Sung Chung // New England Journal of Medicine;4/15/2010, Vol. 362 Issue 15, p1374 

    Background: The potential benefits and risks of the use of dual antiplatelet therapy beyond a 12-month period in patients receiving drug-eluting stents have not been clearly established. Methods: In two trials, we randomly assigned a total of 2701 patients who had received drug-eluting stents...

  • News in brief….  // Reactions Weekly;10/15/2005, Issue 1073, p3 

    Presents news briefs concerning several medical research as of October 2005. Association of angiotensin receptor antagonist use with an increased risk of myocardial infarction; Incidence of nitroglycerin-[glyceryl trinitrate] associated headaches in patients with normal coronary arteries than...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics